Gilead Sciences (NASDAQ:GILD) Given New $115.00 Price Target at Oppenheimer

Gilead Sciences (NASDAQ:GILD - Get Free Report) had its price target raised by equities research analysts at Oppenheimer from $105.00 to $115.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage currently has an "outperform" rating on the biopharmaceutical company's stock. Oppenheimer's price target points to a potential upside of 24.54% from the company's previous close.

Several other equities analysts also recently issued reports on GILD. JPMorgan Chase & Co. upped their price objective on shares of Gilead Sciences from $100.00 to $105.00 and gave the company an "overweight" rating in a research note on Thursday, November 7th. UBS Group raised their price target on Gilead Sciences from $70.00 to $96.00 and gave the stock a "neutral" rating in a research note on Thursday, November 21st. Royal Bank of Canada lifted their price target on Gilead Sciences from $81.00 to $84.00 and gave the stock a "sector perform" rating in a research report on Monday, November 18th. Maxim Group downgraded Gilead Sciences from a "buy" rating to a "hold" rating in a report on Friday, November 8th. Finally, Piper Sandler lifted their target price on shares of Gilead Sciences from $95.00 to $105.00 and gave the company an "overweight" rating in a report on Thursday, November 7th. Twelve analysts have rated the stock with a hold rating, twelve have issued a buy rating and four have given a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $96.43.

Gilead Sciences Stock Up 1.9 %

Shares of GILD traded up $1.75 during mid-day trading on Tuesday, reaching $92.34. The company's stock had a trading volume of 6,433,844 shares, compared to its average volume of 7,068,712. The company's 50 day moving average is $89.33 and its 200 day moving average is $78.89. The stock has a market cap of $115.08 billion, a PE ratio of 1,026.00, a price-to-earnings-growth ratio of 2.86 and a beta of 0.18. Gilead Sciences has a 12-month low of $62.07 and a 12-month high of $98.90. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, topping analysts' consensus estimates of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The company had revenue of $7.55 billion for the quarter, compared to analysts' expectations of $7.01 billion. During the same quarter last year, the company earned $2.29 earnings per share. The firm's revenue for the quarter was up 7.0% on a year-over-year basis. Equities analysts anticipate that Gilead Sciences will post 4.37 EPS for the current fiscal year.

Insider Activity

In other news, insider Johanna Mercier sold 29,357 shares of the business's stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $83.78, for a total value of $2,459,529.46. Following the sale, the insider now owns 78,127 shares of the company's stock, valued at approximately $6,545,480.06. The trade was a 27.31 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Andrew D. Dickinson sold 248,645 shares of the firm's stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $92.76, for a total transaction of $23,064,310.20. Following the transaction, the chief financial officer now owns 138,919 shares of the company's stock, valued at approximately $12,886,126.44. This trade represents a 64.16 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 476,591 shares of company stock valued at $43,747,615. 0.29% of the stock is currently owned by insiders.

Institutional Trading of Gilead Sciences

Several institutional investors and hedge funds have recently bought and sold shares of GILD. Lantz Financial LLC lifted its position in shares of Gilead Sciences by 3.5% in the second quarter. Lantz Financial LLC now owns 24,920 shares of the biopharmaceutical company's stock worth $1,710,000 after purchasing an additional 840 shares in the last quarter. Wealth Enhancement Advisory Services LLC lifted its position in Gilead Sciences by 13.1% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 286,116 shares of the biopharmaceutical company's stock worth $19,630,000 after buying an additional 33,162 shares in the last quarter. 180 Wealth Advisors LLC acquired a new stake in shares of Gilead Sciences during the 2nd quarter valued at $432,000. Baader Bank Aktiengesellschaft purchased a new position in shares of Gilead Sciences during the 2nd quarter valued at $566,000. Finally, Westside Investment Management Inc. increased its stake in shares of Gilead Sciences by 0.6% in the second quarter. Westside Investment Management Inc. now owns 26,526 shares of the biopharmaceutical company's stock worth $1,826,000 after acquiring an additional 152 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company's stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.